Bikash is focused on developing and optimizing novel therapeutic gene editing technologies using RNA-guided nucleases and base editors.
Prior to joining Life Edit Therapeutics, he worked at Asklepios BioPharmaceutical, Inc. (AskBio, subsidiary of Bayer AG) and Taysha Gene Therapies, where he led cell line engineering programs for CRISPR-mediated development of in-vitro disease models for rare diseases. He also investigated cellular and molecular mechanisms for optimal recombinant AAV vector production.
Bikash received his PhD in Microbiology from Purdue University where he studied host pathogen interaction in parasite infected red blood cells in malaria. He continued his studies in the host pathogen interaction as a Postdoctoral Research Fellow at Stanford University, before transitioning to industry.